Author

David James Pinato

Hammersmith HospitalORCID 0000-0002-3529-0103Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

Claudia Angela Maria FulgenziiD· 2 shared Ahmed Omar KasebiD· 1 shared Alberto Giovanni LeoneiD· 1 shared Alessandro ParisiiD· 1 shared Alessia Dalla PriaiD· 1 shared Andrea DalbeniiD· 1 shared Antonio D’AlessioiD· 1 shared Anwaar SaeediD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Claudia Angela Maria FulgenziORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

In depth characterisation of the tumour microenvironment reveals HHV-8 dependent immune regulation in HIV-associated and classic Kaposi Sarcoma.

Claudia Angela Maria Fulgenzi, Alessia Dalla Pria, Yiran Zhao, Alberto Giovanni Leone, Justin Weir, Ignazio Puccio, Krista Tuohinto, Päivi M. Ojala, Mark Bower, David James Pinato

This study compares the tumor microenvironment of HIV-associated and classic Kaposi Sarcoma, finding differences in immune regulation and HHV-8 gene expression.

British Journal of Cancer · Aug 5, 2026Peer-reviewedImmunology

Clinical and molecular characterisation of primary refractoriness to atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma.

Pasquale Lombardi, Erik Ramon‐Gil, Leonardo Brunetti, Giulia Francesca Manfredi, George Merces, Claudia Angela Maria Fulgenzi, Antonio D’Alessio, Aria Torkpour, Ciro Celsa, Bernardo Stefanini, Hannah Yang, Fionnuala Crowley, Thomas Urban Marron, Anwaar Saeed, Matthias Pinter, , David James Pinato

This study identifies clinical and molecular features of primary refractoriness to atezolizumab plus bevacizumab in HCC, showing poor outcomes and an immunosuppressive tumor microenvironment.

bioRxiv · Jul 8, 2025 · PreprintCancer Biology